和黃醫藥(00013.HK)冀索凡替尼今年獲首個海外上市批準 或未來五年達收支平衡
和黃醫藥(00013.HK)新任首席執行官蘇慰國在全年業績記者會上表示,公司兩款已於中國上市的藥品(口夫)(口奎)替尼(愛優特)及索凡替尼(蘇泰達)獲納入國家醫保藥品目錄後銷售增長強勁,今年首兩個月收入增長151%至4,300萬美元。
他指,(口夫)(口奎)替尼的全球三期研究已完成患者招募,預期今年下半年公佈結果。至於索凡替尼去年已於美國及歐洲提交上市申請,目前進展正常,期望今年索凡替尼可獲得首個海外上市批準,集團已就該藥下半年於美國上市作準備。
蘇慰國提到,集團的新藥開發及研究管線豐富,其中血液腫瘤方面有6個臨牀階段的創新藥品,覆蓋幾乎整個血液腫瘤規範。
首席財務官鄭澤鋒則指,兩藥進入國家醫保後今年料可有高雙位數的銷售增長。而集團會持續投入研發,去年的研發開支近3億美元,由於很多藥物正在開發,料未來一至兩年對研發的投入會是高峯,相關開支估計會持續擴大。
他稱集團業務穩健,正健康及持續地發展,隨着更多藥物推出上市,未來五年收入或有十億美元,估計屆時可達收支平衡。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.